1 – 10 of 74
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Therapeutic S100A8/A9 inhibition reduces NADPH oxidase expression, reactive oxygen species production and NLRP3 inflammasome priming in the ischemic myocardium
(
- Contribution to journal › Article
-
Mark
Cardiac ATP production and contractility are favorably regulated by short-term S100A9 blockade after myocardial infarction
2025) In Journal of Advanced Research(
- Contribution to journal › Article
-
Mark
Plasma proteomic and metabolomic profiling of coronary and carotid atherosclerosis in the SCAPIS study - differences and similarities
2025) In Cardiovascular Research(
- Contribution to journal › Article
-
Mark
Calprotectin as a sepsis diagnostic marker in critical care : a retrospective observational study
(
- Contribution to journal › Article
- 2024
-
Mark
Special Issue “COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies”
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Short-term S100A8/A9 Blockade Promotes Cardiac Neovascularization after Myocardial Infarction
2024) In Journal of Cardiovascular Translational Research(
- Contribution to journal › Article
-
Mark
Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome
(
- Contribution to journal › Article
-
Mark
Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation
(
- Contribution to journal › Article
-
Mark
The Gly82Ser polymorphism in the receptor for advanced glycation endproducts increases the risk for coronary events in the general population
(
- Contribution to journal › Article
-
Mark
Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients
(
- Contribution to journal › Article